Jonathan has over 20 years of practical industry experience within the healthcare private equity, start-up, business development, corporate development, and M&A sectors. Jonathan is co-founder and COO of Anthos Therapeutics, a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for high-risk cardiovascular patients. Anthos is a formation of Blackstone (NYSE: BX) and Novartis AG (NYSE: NVS). Jonathan is a Senior Advisor at Blackstone Life Sciences and previously served as Senior Vice President of Strategy & Portfolio Management, and Head of Business Development and Licensing at Merck KGaA (FWB: MRK); CBO, Vedanta Biosciences (LSE: PRTC); Head of M&A and Licensing at Baxter International (NYSE: BAX); and Director of Corporate Development at Serono (NYSE: SRA). Jonathan received a PhD in Molecular Pharmacology and Drug Metabolism from the ICRF (now CRUK), an MBA jointly from the Universities of Versailles, Paris-Saclay, and Webster, St Louis, and both an MA and First-Class BA (Hons) from Cambridge University. Jonathan was previously Vice President of the Swiss PLG, an EMBO fellow at the Swiss Institute of Experimental Cancer Research (ISREC) and has authored several peer-reviewed scientific papers in the fields of oncology and drug metabolism.